Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

Abraaj and Proparco sell part of their stake in Tunisian pharma company Unimed

Global growth investor Abraaj Group and development finance institution Proparco, have sold part of their respective stakes in Unimed, a Tunisian pharmaceutical company to a group of buyers. The buyers include SQM, Blakeney Asset Management and the Tunisian-Kuwaiti Consortium of Development. Abraaj and Proparco exited 83% of their combined stake to the consortium of investors. Established in 1989, Unimed is the second largest local pharmaceutical company in Tunisia, specializing in sterile dosage forms such as liquid and powder injectables, intravenous (IV) solutions and a range of ophthalmic products. Financial details of the deal were not disclosed.


PE Deals,Abraaj Group,Blakeney Asset Management,PROPARCO,SQM,Tunisian pharmaceutical,Tunisian-Kuwaiti Consortium of Development,Unimed,PE Exit